Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -20.81%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
Castle Biosciences reported strong revenue growth and profitability in 2024, with significant increases in test report volumes and cash reserves. However, the anticipated loss of Medicare coverage for DecisionDx-SCC poses a challenge, along with expected declines in the mental health segment. Despite these challenges, the company shows strong financial health and growth potential.Company Guidance
In the Castle Biosciences fourth quarter and full year 2024 conference call, the company reported a revenue of $86.3 million for Q4, marking a 31% increase from the previous year, and a total revenue of $332.1 million for the year, reflecting a 51% growth. The company achieved a total test report volume growth of 36% compared to 2023, with DecisionDx-Melanoma test reports increasing by 8% to 36,008, achieving an approximate 28% market penetration. DecisionDx-SCC test reports grew by 43% to 16,348, while TissueCypher test reports surged by 130% to 20,956. The company's gross margin for 2024 was 78.5%, with an adjusted gross margin of 82%. Castle Biosciences ended the year with $293.1 million in cash, cash equivalents, and marketable securities and reported a full-year net income of $18.2 million, translating to a diluted earnings per share of $0.62. For 2025, the company anticipates total revenue between $280 million and $295 million, accounting for potential loss of Medicare reimbursement for DecisionDx-SCC from April 2025.Strong Revenue Growth
Fourth quarter revenue was $86.3 million, a 31% increase over the fourth quarter of 2023. Full year 2024 revenue was $332.1 million, a 51% increase over 2023.
Increased Test Report Volume
Total test report volume grew by 36% in 2024 compared to 2023.
Cash and Investments Growth
As of December 31, 2024, the company's cash, cash equivalents, and marketable investment securities totaled $293.1 million, a $50 million increase over December 31, 2023.
TissueCypher Test Growth
TissueCypher test reports grew by 130% in 2024 compared to 2023, with 20,956 reports delivered.
Profitability Achieved
Net income for the full year 2024 was $18.2 million compared to a net loss of $57.5 million for 2023.
Positive Adjusted EBITDA
Adjusted EBITDA for the full year 2024 was $75 million compared to a negative $4.4 million in 2023.
---
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $25.28 | $21.68 | -14.24% |
| Nov 04, 2024 | $33.64 | $31.15 | -7.40% |
| Aug 05, 2024 | $21.85 | $24.90 | +13.96% |
| May 02, 2024 | $22.84 | $24.33 | +6.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---